Inhaled Antibiotics for Refractory Nontuberculous Mycobacteria and Non-Cystic Fibrosis Bronchiectasis and the Significance of Mycobacterium abscessus subsp. abscessus Isolation during M. avium Complex Lung Disease Therapy
- PMID: 26131990
- DOI: 10.1164/rccm.201502-0360RR
Inhaled Antibiotics for Refractory Nontuberculous Mycobacteria and Non-Cystic Fibrosis Bronchiectasis and the Significance of Mycobacterium abscessus subsp. abscessus Isolation during M. avium Complex Lung Disease Therapy
Comment on
-
Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease.Ann Am Thorac Soc. 2014 Jan;11(1):30-5. doi: 10.1513/AnnalsATS.201307-231OC. Ann Am Thorac Soc. 2014. PMID: 24460437 Free PMC article.
-
Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials.Lancet Respir Med. 2014 Sep;2(9):738-49. doi: 10.1016/S2213-2600(14)70165-1. Epub 2014 Aug 18. Lancet Respir Med. 2014. PMID: 25154045 Clinical Trial.
-
The significance of Mycobacterium abscessus subspecies abscessus isolation during Mycobacterium avium complex lung disease therapy.Chest. 2015 May;147(5):1369-1375. doi: 10.1378/chest.14-1297. Chest. 2015. PMID: 25357074 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical